Analysis
Website
23andMe (now ChromeCo / TTAM Research Institute)
Analysis
Website
23andMe (now ChromeCo / TTAM Research Institute)
Analysis
Website
23andMe (now ChromeCo / TTAM Research Institute)
Summary
About
Company
23andMe (now ChromeCo / TTAM Research Institute)
Overall Score of Website
17
Analysed on 2026-03-20
Description
23andMe is a direct-to-consumer genetic testing and health insights platform. Originally founded 2006 by Anne Wojcicki (CEO), Linda Avey, and Paul Cusenza; was publicly traded (Nasdaq: ME). Experienced massive decline after Oct 2023 data breach (6.4–15M users affected). Filed Chapter 11 bankruptcy March 23, 2025. Assets (including genetic database of 15M+ users) sold to TTAM Research Institute (Anne Wojcicki nonprofit) for $305M. Sale closed July 14, 2025. Company renamed Chrome Holding Co. (parent) and ChromeCo Inc. (operating entity); continues operating as 23andMe brand at 23andme.com. $30–50M class action settlement (data breach): final approval January 30, 2026; cash claim deadline February 17, 2026 (passed). 5-year Privacy & Medical Shield + Genetic Monitoring benefit available to all settlement class members. 'Don't Sell My DNA Act' pending in Congress (Senate and House versions). Most sub-cases closed January 2026; Chrome Holding Co. case still pending with omnibus hearings March 18-19, 2026. Product: DNA kit + health/ancestry reports + relative matching (14M+ profiles) + carrier status + wellness traits.
Market
Consumer Genomics / Genetic Testing / Direct-to-Consumer Health / Biotechnology
Audience
Existing 23andMe customers concerned about data privacy after bankruptcy; new customers considering DNA testing; privacy advocates and healthcare researchers; journalists and regulators tracking genetic data policy
HQ
San Francisco, CA, USA (nonprofit; formerly Sunnyvale CA)
Summary
Spider Chart
Strategy
3
Strategy
5
Content
8
Content
12
Strategy
15
Navigation
18
SEO
22
Content
25
Brand
28
Freshness
32
Strategy
TTAM Research Institute Ownership (July 14 2025) — Company Renamed ChromeCo — $305M Acquisition — Data Trust Crisis — Homepage Must Address This
Score
3
Severity
Critical
Finding
The Foley Hoag legal update confirms: 'The Court approved the sale of 23andMe's genetic data and personal information assets to TTAM Research Institute, formed by Anne Wojcicki. On July 14, 2025, a notice of the closing of the sale was filed in bankruptcy court. 23andMe Holding Co. and 23andMe, Inc. formally changed their legal names to Chrome Holding Co. and ChromeCo, Inc. respectively.' Every returning 23andMe customer who visits 23andme.com is wondering: who owns my DNA data now? Has the company changed? Is it safe? The bankruptcy, acquisition, and data controversy are the #1 concern for any existing or potential customer. If the homepage does not proactively address this, every visit becomes a trust deficit.
Recommendation
Add a permanent, above-fold homepage trust statement: '23andMe is now owned by TTAM Research Institute, a nonprofit founded by 23andMe co-founder Anne Wojcicki. Your data privacy commitments, your DNA results, and your account access are unchanged. The same privacy policy that protected your data before July 2025 continues to protect it today. [Read our full data commitment →] [Manage your data →]' This statement must appear before any product marketing. The trust crisis is existential — every product promotion placed above the data ownership explanation makes the trust deficit worse.
Strategy
TTAM Research Institute Ownership (July 14 2025) — Company Renamed ChromeCo — $305M Acquisition — Data Trust Crisis — Homepage Must Address This
Score
3
Severity
Critical
Finding
The Foley Hoag legal update confirms: 'The Court approved the sale of 23andMe's genetic data and personal information assets to TTAM Research Institute, formed by Anne Wojcicki. On July 14, 2025, a notice of the closing of the sale was filed in bankruptcy court. 23andMe Holding Co. and 23andMe, Inc. formally changed their legal names to Chrome Holding Co. and ChromeCo, Inc. respectively.' Every returning 23andMe customer who visits 23andme.com is wondering: who owns my DNA data now? Has the company changed? Is it safe? The bankruptcy, acquisition, and data controversy are the #1 concern for any existing or potential customer. If the homepage does not proactively address this, every visit becomes a trust deficit.
Recommendation
Add a permanent, above-fold homepage trust statement: '23andMe is now owned by TTAM Research Institute, a nonprofit founded by 23andMe co-founder Anne Wojcicki. Your data privacy commitments, your DNA results, and your account access are unchanged. The same privacy policy that protected your data before July 2025 continues to protect it today. [Read our full data commitment →] [Manage your data →]' This statement must appear before any product marketing. The trust crisis is existential — every product promotion placed above the data ownership explanation makes the trust deficit worse.
Strategy
TTAM Research Institute Ownership (July 14 2025) — Company Renamed ChromeCo — $305M Acquisition — Data Trust Crisis — Homepage Must Address This
Score
3
Severity
Critical
Finding
The Foley Hoag legal update confirms: 'The Court approved the sale of 23andMe's genetic data and personal information assets to TTAM Research Institute, formed by Anne Wojcicki. On July 14, 2025, a notice of the closing of the sale was filed in bankruptcy court. 23andMe Holding Co. and 23andMe, Inc. formally changed their legal names to Chrome Holding Co. and ChromeCo, Inc. respectively.' Every returning 23andMe customer who visits 23andme.com is wondering: who owns my DNA data now? Has the company changed? Is it safe? The bankruptcy, acquisition, and data controversy are the #1 concern for any existing or potential customer. If the homepage does not proactively address this, every visit becomes a trust deficit.
Recommendation
Add a permanent, above-fold homepage trust statement: '23andMe is now owned by TTAM Research Institute, a nonprofit founded by 23andMe co-founder Anne Wojcicki. Your data privacy commitments, your DNA results, and your account access are unchanged. The same privacy policy that protected your data before July 2025 continues to protect it today. [Read our full data commitment →] [Manage your data →]' This statement must appear before any product marketing. The trust crisis is existential — every product promotion placed above the data ownership explanation makes the trust deficit worse.
Strategy
$30–50M Data Breach Class Action Settlement (Final Approval January 30 2026) — Cash Claims Deadline Passed February 17 2026 — Settlement Communication
Score
5
Severity
Critical
Finding
Multiple sources confirm: 'The 23andMe data breach class action lawsuit settled for $30–50 million. Final court approval January 30, 2026. The February 17, 2026 claim deadline has now passed.' The data breach (October 2023, 6.4–15M users affected) and the class action settlement are the second major trust event affecting 23andMe's customer relationship. Customers who missed the claim deadline may visit the site seeking information. If the settlement is not addressed on the homepage, it appears as if the company is hiding it.
Recommendation
Add a settlement information section to the homepage footer or a dedicated banner: '23andMe Data Breach Settlement: The $30M+ settlement received final court approval on January 30, 2026. The cash claim deadline (February 17, 2026) has passed. Affected customers who filed claims in time will receive distributions as the bankruptcy reconciliation process resolves — which may take several months. All affected customers (regardless of claim filing) are entitled to 5 years of Privacy & Medical Shield + Genetic Monitoring services. [Learn more →]' Proactive settlement communication is required transparency for a company that has positioned itself as a trusted steward of genetic data.
Strategy
$30–50M Data Breach Class Action Settlement (Final Approval January 30 2026) — Cash Claims Deadline Passed February 17 2026 — Settlement Communication
Score
5
Severity
Critical
Finding
Multiple sources confirm: 'The 23andMe data breach class action lawsuit settled for $30–50 million. Final court approval January 30, 2026. The February 17, 2026 claim deadline has now passed.' The data breach (October 2023, 6.4–15M users affected) and the class action settlement are the second major trust event affecting 23andMe's customer relationship. Customers who missed the claim deadline may visit the site seeking information. If the settlement is not addressed on the homepage, it appears as if the company is hiding it.
Recommendation
Add a settlement information section to the homepage footer or a dedicated banner: '23andMe Data Breach Settlement: The $30M+ settlement received final court approval on January 30, 2026. The cash claim deadline (February 17, 2026) has passed. Affected customers who filed claims in time will receive distributions as the bankruptcy reconciliation process resolves — which may take several months. All affected customers (regardless of claim filing) are entitled to 5 years of Privacy & Medical Shield + Genetic Monitoring services. [Learn more →]' Proactive settlement communication is required transparency for a company that has positioned itself as a trusted steward of genetic data.
Strategy
$30–50M Data Breach Class Action Settlement (Final Approval January 30 2026) — Cash Claims Deadline Passed February 17 2026 — Settlement Communication
Score
5
Severity
Critical
Finding
Multiple sources confirm: 'The 23andMe data breach class action lawsuit settled for $30–50 million. Final court approval January 30, 2026. The February 17, 2026 claim deadline has now passed.' The data breach (October 2023, 6.4–15M users affected) and the class action settlement are the second major trust event affecting 23andMe's customer relationship. Customers who missed the claim deadline may visit the site seeking information. If the settlement is not addressed on the homepage, it appears as if the company is hiding it.
Recommendation
Add a settlement information section to the homepage footer or a dedicated banner: '23andMe Data Breach Settlement: The $30M+ settlement received final court approval on January 30, 2026. The cash claim deadline (February 17, 2026) has passed. Affected customers who filed claims in time will receive distributions as the bankruptcy reconciliation process resolves — which may take several months. All affected customers (regardless of claim filing) are entitled to 5 years of Privacy & Medical Shield + Genetic Monitoring services. [Learn more →]' Proactive settlement communication is required transparency for a company that has positioned itself as a trusted steward of genetic data.
Content
Don't Sell My DNA Act' — Pending Congressional Legislation — Regulatory Risk Not Addressed on Homepage
Score
8
Severity
High
Finding
The White and Williams legal article confirms: 'The bipartisan Don't Sell My DNA Act introduced in May by Senators Grassley, Cornyn, and Klobuchar remains pending. That bill now has a House companion (H.R. 4492), introduced on July 17, 2025 by Reps. Ben Cline and Zoe Lofgren. The legislation seeks to amend the Bankruptcy Code's definition of personally identifiable information to include genetic information and to require written notice and affirmative consumer consent as a condition to any attempted sale in bankruptcy proceedings.' This pending legislation directly names 23andMe as the case study for why the law is needed. If 23andMe does not address this legislation on its homepage, customers discovering the bill will assume the company is opposed to genetic data protection.
Recommendation
Add a policy page and homepage link: '23andMe and genetic data protection legislation: We support stronger protections for genetic data in bankruptcy proceedings. [Read our position on the Don't Sell My DNA Act →]' Taking a proactive, supportive stance on the legislation demonstrates that TTAM/23andMe is genuinely committed to data protection, not just compliance with existing requirements. This is a brand differentiation opportunity — being the company that advocates for its customers' genetic privacy rights.
Content
Don't Sell My DNA Act' — Pending Congressional Legislation — Regulatory Risk Not Addressed on Homepage
Score
8
Severity
High
Finding
The White and Williams legal article confirms: 'The bipartisan Don't Sell My DNA Act introduced in May by Senators Grassley, Cornyn, and Klobuchar remains pending. That bill now has a House companion (H.R. 4492), introduced on July 17, 2025 by Reps. Ben Cline and Zoe Lofgren. The legislation seeks to amend the Bankruptcy Code's definition of personally identifiable information to include genetic information and to require written notice and affirmative consumer consent as a condition to any attempted sale in bankruptcy proceedings.' This pending legislation directly names 23andMe as the case study for why the law is needed. If 23andMe does not address this legislation on its homepage, customers discovering the bill will assume the company is opposed to genetic data protection.
Recommendation
Add a policy page and homepage link: '23andMe and genetic data protection legislation: We support stronger protections for genetic data in bankruptcy proceedings. [Read our position on the Don't Sell My DNA Act →]' Taking a proactive, supportive stance on the legislation demonstrates that TTAM/23andMe is genuinely committed to data protection, not just compliance with existing requirements. This is a brand differentiation opportunity — being the company that advocates for its customers' genetic privacy rights.
Content
Don't Sell My DNA Act' — Pending Congressional Legislation — Regulatory Risk Not Addressed on Homepage
Score
8
Severity
High
Finding
The White and Williams legal article confirms: 'The bipartisan Don't Sell My DNA Act introduced in May by Senators Grassley, Cornyn, and Klobuchar remains pending. That bill now has a House companion (H.R. 4492), introduced on July 17, 2025 by Reps. Ben Cline and Zoe Lofgren. The legislation seeks to amend the Bankruptcy Code's definition of personally identifiable information to include genetic information and to require written notice and affirmative consumer consent as a condition to any attempted sale in bankruptcy proceedings.' This pending legislation directly names 23andMe as the case study for why the law is needed. If 23andMe does not address this legislation on its homepage, customers discovering the bill will assume the company is opposed to genetic data protection.
Recommendation
Add a policy page and homepage link: '23andMe and genetic data protection legislation: We support stronger protections for genetic data in bankruptcy proceedings. [Read our position on the Don't Sell My DNA Act →]' Taking a proactive, supportive stance on the legislation demonstrates that TTAM/23andMe is genuinely committed to data protection, not just compliance with existing requirements. This is a brand differentiation opportunity — being the company that advocates for its customers' genetic privacy rights.
Content
5 Years of Privacy & Medical Shield + Genetic Monitoring — Settlement Benefit — Existing Customers Not Aware
Score
12
Severity
Medium
Finding
Settlement documentation confirms: 'If you do nothing, you will still be bound by the Settlement, and you will retain the opportunity to participate in five years of Privacy & Medical Shield + Genetic Monitoring services.' The 5-year genetic monitoring benefit is available to all class members who did not opt out — but many customers may not know they are eligible or how to activate it. If this benefit is not prominently communicated on the homepage, the company is not delivering value it has committed to provide.
Recommendation
Feature the monitoring benefit prominently: '5 years of genetic monitoring — free for affected customers. As part of the data breach settlement, eligible 23andMe customers receive 5 years of Privacy & Medical Shield + Genetic Monitoring at no cost. [Activate your monitoring →]' Proactively delivering the settlement benefit converts a negative experience (data breach victim) into a positive touch point (company that follows through on its commitments). This is an opportunity to rebuild trust, not just a legal obligation.
Content
5 Years of Privacy & Medical Shield + Genetic Monitoring — Settlement Benefit — Existing Customers Not Aware
Score
12
Severity
Medium
Finding
Settlement documentation confirms: 'If you do nothing, you will still be bound by the Settlement, and you will retain the opportunity to participate in five years of Privacy & Medical Shield + Genetic Monitoring services.' The 5-year genetic monitoring benefit is available to all class members who did not opt out — but many customers may not know they are eligible or how to activate it. If this benefit is not prominently communicated on the homepage, the company is not delivering value it has committed to provide.
Recommendation
Feature the monitoring benefit prominently: '5 years of genetic monitoring — free for affected customers. As part of the data breach settlement, eligible 23andMe customers receive 5 years of Privacy & Medical Shield + Genetic Monitoring at no cost. [Activate your monitoring →]' Proactively delivering the settlement benefit converts a negative experience (data breach victim) into a positive touch point (company that follows through on its commitments). This is an opportunity to rebuild trust, not just a legal obligation.
Content
5 Years of Privacy & Medical Shield + Genetic Monitoring — Settlement Benefit — Existing Customers Not Aware
Score
12
Severity
Medium
Finding
Settlement documentation confirms: 'If you do nothing, you will still be bound by the Settlement, and you will retain the opportunity to participate in five years of Privacy & Medical Shield + Genetic Monitoring services.' The 5-year genetic monitoring benefit is available to all class members who did not opt out — but many customers may not know they are eligible or how to activate it. If this benefit is not prominently communicated on the homepage, the company is not delivering value it has committed to provide.
Recommendation
Feature the monitoring benefit prominently: '5 years of genetic monitoring — free for affected customers. As part of the data breach settlement, eligible 23andMe customers receive 5 years of Privacy & Medical Shield + Genetic Monitoring at no cost. [Activate your monitoring →]' Proactively delivering the settlement benefit converts a negative experience (data breach victim) into a positive touch point (company that follows through on its commitments). This is an opportunity to rebuild trust, not just a legal obligation.
Strategy
TTAM Nonprofit Status — 'Same Business, Same Employees, Familiar Leaders, Same Privacy Policies' — Bankruptcy Judge Quote — Homepage Trust Signal
Score
15
Severity
Medium
Finding
The Public Citizen testimony quotes the bankruptcy judge: TTAM is 'the same business, the same employees, familiar leaders, and the same privacy policies.' This is actually the strongest possible continuity argument — the judge himself confirmed the operational continuity. If 23andme.com's homepage uses this judicial confirmation of continuity as a trust anchor, it directly addresses the 'new owner might change the rules' customer fear.
Recommendation
Quote the judge: 'A federal bankruptcy judge confirmed: TTAM Research Institute represents the same business, the same employees, familiar leaders, and the same privacy policies as 23andMe. Your data has not moved. Your protections have not changed. Your results are still yours.' Judicial language carries credibility that marketing copy cannot — it signals that the data protection commitment has been reviewed by an independent authority and found to be genuine.
Strategy
TTAM Nonprofit Status — 'Same Business, Same Employees, Familiar Leaders, Same Privacy Policies' — Bankruptcy Judge Quote — Homepage Trust Signal
Score
15
Severity
Medium
Finding
The Public Citizen testimony quotes the bankruptcy judge: TTAM is 'the same business, the same employees, familiar leaders, and the same privacy policies.' This is actually the strongest possible continuity argument — the judge himself confirmed the operational continuity. If 23andme.com's homepage uses this judicial confirmation of continuity as a trust anchor, it directly addresses the 'new owner might change the rules' customer fear.
Recommendation
Quote the judge: 'A federal bankruptcy judge confirmed: TTAM Research Institute represents the same business, the same employees, familiar leaders, and the same privacy policies as 23andMe. Your data has not moved. Your protections have not changed. Your results are still yours.' Judicial language carries credibility that marketing copy cannot — it signals that the data protection commitment has been reviewed by an independent authority and found to be genuine.
Strategy
TTAM Nonprofit Status — 'Same Business, Same Employees, Familiar Leaders, Same Privacy Policies' — Bankruptcy Judge Quote — Homepage Trust Signal
Score
15
Severity
Medium
Finding
The Public Citizen testimony quotes the bankruptcy judge: TTAM is 'the same business, the same employees, familiar leaders, and the same privacy policies.' This is actually the strongest possible continuity argument — the judge himself confirmed the operational continuity. If 23andme.com's homepage uses this judicial confirmation of continuity as a trust anchor, it directly addresses the 'new owner might change the rules' customer fear.
Recommendation
Quote the judge: 'A federal bankruptcy judge confirmed: TTAM Research Institute represents the same business, the same employees, familiar leaders, and the same privacy policies as 23andMe. Your data has not moved. Your protections have not changed. Your results are still yours.' Judicial language carries credibility that marketing copy cannot — it signals that the data protection commitment has been reviewed by an independent authority and found to be genuine.
Navigation
Account Data Export and Deletion — 'Manage Your Data' — Critical Customer Action After Bankruptcy News
Score
18
Severity
Medium
Finding
With the bankruptcy, ownership change, and breach settlement all dominating news coverage of 23andMe, a significant portion of existing customers have attempted to export or delete their genetic data. If the homepage does not have a prominent 'Manage your data' link — allowing customers to easily download their raw DNA data, delete their account, or review their privacy settings — the company appears to be hiding these options.
Recommendation
Add a 'Manage your data' link as the second item in the homepage header navigation, immediately after the login button: '[Manage Your Data →] — Download your DNA results · Review your privacy settings · Delete your account.' Making data management visible and easy is both a privacy best practice and a trust signal. Customers who can easily manage their data are more likely to trust the company than those who have to dig through settings menus to find deletion options.
Navigation
Account Data Export and Deletion — 'Manage Your Data' — Critical Customer Action After Bankruptcy News
Score
18
Severity
Medium
Finding
With the bankruptcy, ownership change, and breach settlement all dominating news coverage of 23andMe, a significant portion of existing customers have attempted to export or delete their genetic data. If the homepage does not have a prominent 'Manage your data' link — allowing customers to easily download their raw DNA data, delete their account, or review their privacy settings — the company appears to be hiding these options.
Recommendation
Add a 'Manage your data' link as the second item in the homepage header navigation, immediately after the login button: '[Manage Your Data →] — Download your DNA results · Review your privacy settings · Delete your account.' Making data management visible and easy is both a privacy best practice and a trust signal. Customers who can easily manage their data are more likely to trust the company than those who have to dig through settings menus to find deletion options.
Navigation
Account Data Export and Deletion — 'Manage Your Data' — Critical Customer Action After Bankruptcy News
Score
18
Severity
Medium
Finding
With the bankruptcy, ownership change, and breach settlement all dominating news coverage of 23andMe, a significant portion of existing customers have attempted to export or delete their genetic data. If the homepage does not have a prominent 'Manage your data' link — allowing customers to easily download their raw DNA data, delete their account, or review their privacy settings — the company appears to be hiding these options.
Recommendation
Add a 'Manage your data' link as the second item in the homepage header navigation, immediately after the login button: '[Manage Your Data →] — Download your DNA results · Review your privacy settings · Delete your account.' Making data management visible and easy is both a privacy best practice and a trust signal. Customers who can easily manage their data are more likely to trust the company than those who have to dig through settings menus to find deletion options.
SEO
23andMe bankruptcy' / 'Is 23andMe safe' / 'Who owns 23andMe now' — Top Search Queries Arriving at Homepage
Score
22
Severity
High
Finding
The top customer search queries arriving at 23andme.com in 2025-2026 are: '23andMe bankruptcy update,' 'who owns 23andMe now,' 'is 23andMe safe after bankruptcy,' '23andMe data breach settlement,' '23andMe TTAM acquisition.' These are anxiety-driven searches from existing customers who are concerned about their genetic data. If the homepage does not directly address these queries in its above-fold content, every visitor arriving from these searches bounces immediately — increasing both the trust deficit and the SEO bounce rate.
Recommendation
Set the homepage meta title to: '23andMe — DNA Testing, Now Owned by TTAM Research Institute (Nonprofit). Your Data Is Protected.' Set the meta description to: '23andMe is now a TTAM Research Institute nonprofit. Your DNA data, privacy commitments, and account access are unchanged after July 2025. Learn what this means for your data →' These meta tags directly answer the top anxiety-driven searches and reduce the bounce rate for users arriving from bankruptcy-related searches.
SEO
23andMe bankruptcy' / 'Is 23andMe safe' / 'Who owns 23andMe now' — Top Search Queries Arriving at Homepage
Score
22
Severity
High
Finding
The top customer search queries arriving at 23andme.com in 2025-2026 are: '23andMe bankruptcy update,' 'who owns 23andMe now,' 'is 23andMe safe after bankruptcy,' '23andMe data breach settlement,' '23andMe TTAM acquisition.' These are anxiety-driven searches from existing customers who are concerned about their genetic data. If the homepage does not directly address these queries in its above-fold content, every visitor arriving from these searches bounces immediately — increasing both the trust deficit and the SEO bounce rate.
Recommendation
Set the homepage meta title to: '23andMe — DNA Testing, Now Owned by TTAM Research Institute (Nonprofit). Your Data Is Protected.' Set the meta description to: '23andMe is now a TTAM Research Institute nonprofit. Your DNA data, privacy commitments, and account access are unchanged after July 2025. Learn what this means for your data →' These meta tags directly answer the top anxiety-driven searches and reduce the bounce rate for users arriving from bankruptcy-related searches.
SEO
23andMe bankruptcy' / 'Is 23andMe safe' / 'Who owns 23andMe now' — Top Search Queries Arriving at Homepage
Score
22
Severity
High
Finding
The top customer search queries arriving at 23andme.com in 2025-2026 are: '23andMe bankruptcy update,' 'who owns 23andMe now,' 'is 23andMe safe after bankruptcy,' '23andMe data breach settlement,' '23andMe TTAM acquisition.' These are anxiety-driven searches from existing customers who are concerned about their genetic data. If the homepage does not directly address these queries in its above-fold content, every visitor arriving from these searches bounces immediately — increasing both the trust deficit and the SEO bounce rate.
Recommendation
Set the homepage meta title to: '23andMe — DNA Testing, Now Owned by TTAM Research Institute (Nonprofit). Your Data Is Protected.' Set the meta description to: '23andMe is now a TTAM Research Institute nonprofit. Your DNA data, privacy commitments, and account access are unchanged after July 2025. Learn what this means for your data →' These meta tags directly answer the top anxiety-driven searches and reduce the bounce rate for users arriving from bankruptcy-related searches.
Content
Health + Ancestry Reports — Core Product Value — Still Available — Not Confirmed as Hero After Bankruptcy News Coverage
Score
25
Severity
Medium
Finding
Despite the ownership change and breach, 23andMe's core product — health and ancestry DNA reports — continues to function and provide value. New customers considering the service may be deterred by the bankruptcy and breach news without understanding that the product itself is operational and valuable. The homepage needs to balance trust communication (ownership/breach/settlement) with product communication (the service still works and provides genuine health insights).
Recommendation
After the trust communication section (above-fold ownership/settlement statement), add a product value section: '23andMe still provides: Ancestry composition across 2,000+ regions · Health predisposition reports for 20+ conditions · Carrier status for 40+ inherited conditions · Wellness traits and reports · Relative matching with 14 million+ profiles.' This two-section homepage structure — trust first, product second — respects the customer's primary concern (is my data safe?) while still communicating the product value that makes the service worth using.
Content
Health + Ancestry Reports — Core Product Value — Still Available — Not Confirmed as Hero After Bankruptcy News Coverage
Score
25
Severity
Medium
Finding
Despite the ownership change and breach, 23andMe's core product — health and ancestry DNA reports — continues to function and provide value. New customers considering the service may be deterred by the bankruptcy and breach news without understanding that the product itself is operational and valuable. The homepage needs to balance trust communication (ownership/breach/settlement) with product communication (the service still works and provides genuine health insights).
Recommendation
After the trust communication section (above-fold ownership/settlement statement), add a product value section: '23andMe still provides: Ancestry composition across 2,000+ regions · Health predisposition reports for 20+ conditions · Carrier status for 40+ inherited conditions · Wellness traits and reports · Relative matching with 14 million+ profiles.' This two-section homepage structure — trust first, product second — respects the customer's primary concern (is my data safe?) while still communicating the product value that makes the service worth using.
Content
Health + Ancestry Reports — Core Product Value — Still Available — Not Confirmed as Hero After Bankruptcy News Coverage
Score
25
Severity
Medium
Finding
Despite the ownership change and breach, 23andMe's core product — health and ancestry DNA reports — continues to function and provide value. New customers considering the service may be deterred by the bankruptcy and breach news without understanding that the product itself is operational and valuable. The homepage needs to balance trust communication (ownership/breach/settlement) with product communication (the service still works and provides genuine health insights).
Recommendation
After the trust communication section (above-fold ownership/settlement statement), add a product value section: '23andMe still provides: Ancestry composition across 2,000+ regions · Health predisposition reports for 20+ conditions · Carrier status for 40+ inherited conditions · Wellness traits and reports · Relative matching with 14 million+ profiles.' This two-section homepage structure — trust first, product second — respects the customer's primary concern (is my data safe?) while still communicating the product value that makes the service worth using.
Brand
ChromeCo' Legal Entity vs '23andMe' Brand — Customer Confusion — Homepage Must Clarify
Score
28
Severity
Low
Finding
The bankruptcy records confirm: '23andMe, Inc. formally changed its legal name to ChromeCo, Inc.' The brand name '23andMe' continues as the product/service brand, but the legal entity is now ChromeCo. Customers who discover the legal name change through press coverage may visit the site confused about whether 23andme.com is the same company they signed up with.
Recommendation
Add a footer note: '23andMe is a product of ChromeCo, Inc. (formerly 23andMe, Inc.), a wholly owned subsidiary of TTAM Research Institute. The 23andMe brand, product, and service continue unchanged. ChromeCo is a legal entity name change — not a product or service change.' This disambiguation prevents customer confusion from the legal name change without burying the brand under corporate structure complexity.
Brand
ChromeCo' Legal Entity vs '23andMe' Brand — Customer Confusion — Homepage Must Clarify
Score
28
Severity
Low
Finding
The bankruptcy records confirm: '23andMe, Inc. formally changed its legal name to ChromeCo, Inc.' The brand name '23andMe' continues as the product/service brand, but the legal entity is now ChromeCo. Customers who discover the legal name change through press coverage may visit the site confused about whether 23andme.com is the same company they signed up with.
Recommendation
Add a footer note: '23andMe is a product of ChromeCo, Inc. (formerly 23andMe, Inc.), a wholly owned subsidiary of TTAM Research Institute. The 23andMe brand, product, and service continue unchanged. ChromeCo is a legal entity name change — not a product or service change.' This disambiguation prevents customer confusion from the legal name change without burying the brand under corporate structure complexity.
Brand
ChromeCo' Legal Entity vs '23andMe' Brand — Customer Confusion — Homepage Must Clarify
Score
28
Severity
Low
Finding
The bankruptcy records confirm: '23andMe, Inc. formally changed its legal name to ChromeCo, Inc.' The brand name '23andMe' continues as the product/service brand, but the legal entity is now ChromeCo. Customers who discover the legal name change through press coverage may visit the site confused about whether 23andme.com is the same company they signed up with.
Recommendation
Add a footer note: '23andMe is a product of ChromeCo, Inc. (formerly 23andMe, Inc.), a wholly owned subsidiary of TTAM Research Institute. The 23andMe brand, product, and service continue unchanged. ChromeCo is a legal entity name change — not a product or service change.' This disambiguation prevents customer confusion from the legal name change without burying the brand under corporate structure complexity.
Freshness
Ongoing Bankruptcy Reconciliation — Chrome Holding Co. Case — March 2026 Omnibus Hearings — Status Updates Needed
Score
32
Severity
Low
Finding
The bankruptcy court docket confirms: 'Pursuant to an order dated January 21, 2026, the Chapter 11 cases for all Debtors other than Chrome Holding Co. are now closed. The remaining case is pending. Omnibus hearings scheduled March 18-19, 2026.' The bankruptcy is not entirely complete — one case remains pending. Settlement payment distribution is delayed until the bankruptcy reconciliation resolves, which 'may take several months or longer.' If the homepage does not provide a status update on the ongoing proceedings, customers who are waiting for settlement payments have no transparency.
Recommendation
Add a status page: 23andme.com/settlement-status — with a timeline of completed milestones (bankruptcy filed March 2025, TTAM acquisition closed July 2025, settlement approved January 2026, claim deadline February 2026) and pending items (remaining bankruptcy case, payment distribution timeline). Monthly updates to this page demonstrate ongoing transparency and reduce customer support volume from customers asking 'when will I receive my settlement payment?'
Freshness
Ongoing Bankruptcy Reconciliation — Chrome Holding Co. Case — March 2026 Omnibus Hearings — Status Updates Needed
Score
32
Severity
Low
Finding
The bankruptcy court docket confirms: 'Pursuant to an order dated January 21, 2026, the Chapter 11 cases for all Debtors other than Chrome Holding Co. are now closed. The remaining case is pending. Omnibus hearings scheduled March 18-19, 2026.' The bankruptcy is not entirely complete — one case remains pending. Settlement payment distribution is delayed until the bankruptcy reconciliation resolves, which 'may take several months or longer.' If the homepage does not provide a status update on the ongoing proceedings, customers who are waiting for settlement payments have no transparency.
Recommendation
Add a status page: 23andme.com/settlement-status — with a timeline of completed milestones (bankruptcy filed March 2025, TTAM acquisition closed July 2025, settlement approved January 2026, claim deadline February 2026) and pending items (remaining bankruptcy case, payment distribution timeline). Monthly updates to this page demonstrate ongoing transparency and reduce customer support volume from customers asking 'when will I receive my settlement payment?'
Freshness
Ongoing Bankruptcy Reconciliation — Chrome Holding Co. Case — March 2026 Omnibus Hearings — Status Updates Needed
Score
32
Severity
Low
Finding
The bankruptcy court docket confirms: 'Pursuant to an order dated January 21, 2026, the Chapter 11 cases for all Debtors other than Chrome Holding Co. are now closed. The remaining case is pending. Omnibus hearings scheduled March 18-19, 2026.' The bankruptcy is not entirely complete — one case remains pending. Settlement payment distribution is delayed until the bankruptcy reconciliation resolves, which 'may take several months or longer.' If the homepage does not provide a status update on the ongoing proceedings, customers who are waiting for settlement payments have no transparency.
Recommendation
Add a status page: 23andme.com/settlement-status — with a timeline of completed milestones (bankruptcy filed March 2025, TTAM acquisition closed July 2025, settlement approved January 2026, claim deadline February 2026) and pending items (remaining bankruptcy case, payment distribution timeline). Monthly updates to this page demonstrate ongoing transparency and reduce customer support volume from customers asking 'when will I receive my settlement payment?'